[1]
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013.
[2]
Laxminarayan, R.; Bhutta, Z.A. Antimicrobial resistance a threat to neonate survival. Lancet Glob. Health, 2016, 4(10), e676-e677.
[3]
Roca, I.; Akova, M.; Baquero, F.; Carlet, J.; Cavaleri, M.; Coenen, S.; Cohen, J.; Findlay, D.; Gyssens, I.; Heure, O.E.; Kahlmeter, G.; Kruse, H.; Laxminarayan, R.; Liébana, E.; López-Cerero, L.; MacGowan, A.; Martins, M.; Rodríguez-Baño, J.; Rolain, J.M.; Segovia, C.; Sigauque, B.; Tacconelli, E.; Wellington, E.; Vila, J. The global threat of antimicrobial resistance: Science for intervention. New Microbes New Infect., 2015, 6, 22-29.
[4]
Laxminarayan, R.; Matsoso, P.; Pant, S.; Brower, C.; Røttingen, J.A.; Klugman, K.; Davies, S. Access to effective antimicrobials: A worldwide challenge. Lancet, 2016, 387(10014), 168-175.
[5]
Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations, 2014.
[6]
Laxminarayan, R.; Duse, A.; Wattal, C.; Zaidi, A.K.M.; Wertheim, H.F.L.; Sumpradit, N.; Vlieghe, E.; Hara, G.L.; Gould, I.M.; Goossens, H.; Greko, C.; So, A.D.; Bigdeli, M.; Tomson, G.; Woodhouse, W.; Ombaka, E.; Peralta, A.Q.; Qamar, F.N.; Mir, F.; Kariuki, S.; Bhutta, Z.A.; Coates, A.; Bergstrom, R.; Wright, G.D.; Brown, E.D.; Cars, O. Antibiotic resistance-the need for global solutions. Lancet Infect. Dis., 2013, 13(12), 1057-1098.
[7]
Potter, A.; Gerdts, V.; Littel-van den Hurk, Sv. Veterinary vaccines: Alternatives to antibiotics? Anim. Health Res. Rev., 2008, 9(2), 187-199.
[8]
Siegrist, C.A. Vaccine immunology. In: Vaccines; Plotkin, S.; Orenstein W.; Offit, P, 6th ed; Elsevier: Amsterdam, 2013; pp. 14-32.
[9]
Pasquale, A.; Preiss, S.; Silva, F.; Garçon, N. Vaccine adjuvants: From 1920 to 2015 and beyond. Vaccines, 2015, 3(2), 320-343.
[10]
Reed, S.G.; Orr, M.T.; Fox, C.B. Key roles of adjuvants in modern vaccines. Nat. Med., 2013, 19(12), 1597-1608.
[11]
Moyer, T.J.; Zmolek, A.C.; Irvine, D.J. Beyond antigens and adjuvants: Formulating future vaccines. J. Clin. Invest., 2016, 126(3), 799-808.
[12]
Bahar, A.A.; Ren, D. Antimicrobial peptides. Pharmaceuticals, 2013, 6, 1543-1575.
[13]
Haney, E.F.; Mansour, S.C.; Hancock, R.E.W. Antimicrobial peptides: An introduction. Methods Mol. Biol., 2017, 1548, 3-22.
[14]
Baindara, P.; Chaudhry, V.; Mittal, G.; Liao, L.M.; Matos, C.O.; Khatri, N.; Franco, O.L.; Patil, P.B.; Korpole, S. Characterization of the antimicrobial peptide penisin, a class Ia novel lantibiotic from paenibacillus sp. strain A3. Antimicrob. Agents Chemother., 2015, 60(1), 580-591.
[15]
Gordon, Y.J.; Romanowski, E.G.; McDermott, A.M. Mini review: A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res., 2005, 30(7), 505-515.
[16]
Baindara, P.; Korpole, S. Lipopeptides: Status and strategies to control fungal infection. In: Recent Trends in Antifungal Agents and Antifungal Therapy; Basak, A.; Chakraborty, R.; Mandal, M.S., Eds.; Springer India: New Delhi, 2016; pp. 97-121.
[17]
Zhang, L.; Gallo, R.L. Antimicrobial peptides. Curr. Biol., 2016, 26(1), R14-R19.
[18]
Pinheiro Da Silva, F.; MacHado, M.C.C. Antimicrobial peptides: Clinical relevance and therapeutic implications. Peptides, 2012, 36(2), 308-314.
[19]
van Dissel, J.T.; Arend, S.M.; Prins, C.; Bang, P.; Tingskov, P.N.; Lingnau, K.; Nouta, J.; Klein, M.R.; Rosenkrands, I.; Ottenhoff, T.H.M. Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine, 2010, 28(20), 3571-3581.
[20]
Schellack, C.; Prinz, K.; Egyed, A.; Fritz, J.H.; Wittmann, B.; Ginzler, M.; Swatosch, G.; Zauner, W.; Kast, C.; Akira, S.; von Gabain, A.; Buschle, M.; Lingnau, K. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine, 2006, 24(26), 5461-5472.
[21]
Mandal, S.M.; Pati, B.R.; Chakraborty, R.; Franco, O.L. New insights into the bioactivity of peptides from probiotics. Front. Biosci., 2016, 8, 450.
[22]
Baindara, P.; Gautam, A.; Raghava, G.P.S.; Korpole, S. Anticancer properties of a defensin like class IId bacteriocin laterosporulin10. Sci. Rep., 2017, 7, 46541.
[23]
Baindara, P.; Singh, N.; Ranjan, M.; Nallabelli, N.; Chaudhry, V.; Pathania, G.L.; Sharma, N.; Kumar, A.; Patil, P.B.; Korpole, S. Laterosporulin10: A novel defensin like class IId bacteriocin from brevibacillus sp. Strain SKDU10 with inhibitory activity against microbial pathogens. Microbiology, 2016, 162(8), 1286-1299.
[24]
Baindara, P.; Kapoor, A.; Korpole, S.; Grover, V. Cysteine-rich low molecular weight antimicrobial peptides from brevibacillus and related genera for biotechnological applications. World J. Microbiol. Biotechnol., 2017, 33(6), 124.
[25]
Hancock, R.E.W.; Sahl, H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol., 2006, 24(12), 1551-1557.
[26]
Atkins, K.E.; Flasche, S. Vaccination to reduce antimicrobial resistance. Lancet Glob. Health, 2018, 6(3), 252.
[27]
Van De Sande-Bruinsma, N.; Grundmann, H.; Verloo, D.; Tiemersma, E.; Monen, J.; Goossens, H.; Ferech, M.; Mittermayer, H.; Metz, S.; Koller, W. European antimicrobial resistance surveillance system group; European surveillance of antimicrobial consumption project group. Antimicrobial drug use and resistance in europe. Emerg. Infect. Dis., 2008, 14(11), 1722-1730.
[28]
O’Neill, J. Tackling drug-resistant infections globally: Final report and recommendations. Rev. Antimicrob. Resist., 2016, 1, 84.
[29]
Heinsen, F.A.; Knecht, H.; Neulinger, S.C.; Schmitz, R.A.; Knecht, C.; Kühbacher, T.; Rosenstiel, P.C.; Schreiber, S.; Friedrichs, A.K.; Ott, S.J. Dynamic changes of the luminal and mucosaassociated gut microbiota during and after antibiotic therapy with paromomycin. Gut Microbes, 2015, 6(4), 243-254.
[30]
Ferrer, M.; Martins dos Santos, V.A.P.; Ott, S.J.; Moya, A. Gut microbiota disturbance during antibiotic therapy: A multi-omic approach. Gut Microbes, 2014, 5(1), 64-70.
[31]
Iizumi, T.; Battaglia, T.; Ruiz, V.; Perez Perez, G.I. Gut microbiome and antibiotics. Arch. Med. Res., 2017, 48, 727-734.
[32]
Olekhnovich, E.I.; Vasilyev, A.T.; Ulyantsev, V.I.; Kostryukova, E.S.; Tyakht, A.V. MetaCherchant: Analyzing genomic context of antibiotic resistance genes in gut microbiota. Bioinformatics, 2018, 34(3), 434-444.
[33]
Van Schaik, W. The human gut resistome. Philos. Trans. R. Soc. Biol. Sci., 2015, 370(1670), 20140087-20140087.
[34]
García-Quintanilla, M.; Pulido, M.R.; Carretero-Ledesma, M.; McConnell, M.J. Vaccines for antibiotic-resistant bacteria: Possibility or pipe dream? Trends Pharmacol. Sci., 2016, 37(2), 143-152.
[35]
Jansen, K.U.; Knirsch, C.; Anderson, A.S. The role of vaccines in preventing bacterial antimicrobial resistance. Nat. Med., 2018, 24(1), 10-20.
[36]
Fine, P.E.M. Herd immunity: History, theory, practice. Epidemiol. Rev., 1993, 15(2), 265.
[37]
Metcalf, C.J.E.; Ferrari, M.; Graham, A.L.; Grenfell, B.T. Understanding herd immunity. Trends Immunol., 2015, 36(12), 753-755.
[38]
Siefert, A.L.; Caplan, M.J.; Fahmy, T.M. Artificial bacterial biomimetic nanoparticles synergize pathogen-associated molecular patterns for vaccine efficacy. Biomaterials, 2016, 97, 85-96.
[39]
Demento, S.L.; Siefert, A.L.; Bandyopadhyay, A.; Sharp, F.A.; Fahmy, T.M. Pathogen-associated molecular patterns on biomaterials: A paradigm for engineering new vaccines. Trends Biotechnol., 2011, 29(6), 294-306.
[40]
Testa, J.S.; Philip, R. Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications. Future Virol., 2012, 7(11), 1077-1088.
[41]
Kuo, T.; Wang, C.; Badakhshan, T.; Chilukuri, S.; BenMohamed, L. The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine. Vaccine, 2014, 32(50), 6733-6745.
[42]
Li, L.; Yin, H.; An, Z.; Feng, Z. Considerations for developing an immunization strategy with enterovirus 71 vaccine. Vaccine, 2015, 33(9), 1107-1112.
[43]
Corti, D.; Voss, J.; Gamblin, S.J.; Codoni, G.; Macagno, A.; Jarrossay, D.; Vachieri, S.G.; Pinna, D.; Minola, A.; Vanzetta, F.; Silacci, C.; Fernandez-Rodriguez, B.M.; Agatic, G.; Bianchi, S.; Giacchetto-Sasselli, I.; Calder, L.; Sallusto, F.; Collins, P.; Haire, L.F.; Temperton, N.; Langedijk, J.P.; Skehel, J.J.; Lanzavecchia, A. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science, 2011, 333(6044), 850-856.
[44]
Marco, M.D.; Peper, J.K.; Rammensee, H.G. Identification of immunogenic epitopes by MS/MS. Cancer J., 2017, 23(2), 102-107.
[45]
Hager-Braun, C.; Tomer, K.B. Determination of protein-derived epitopes by mass spectrometry. Expert Rev. Proteomics, 2005, 2(5), 745-756.
[46]
Chen, W.H.; Sun, P.P.; Lu, Y.; Guo, W.W.; Huang, Y.X.; Ma, Z.Q. MimoPro: A more efficient web-based tool for epitope prediction using phage display libraries. BMC Bioinformatics, 2011, 12, 199.
[47]
Huang, J.; Gutteridge, A.; Honda, W.; Kanehisa, M. MIMOX: A web tool for phage display based epitope mapping. BMC Bioinformatics, 2006, 7, 451.
[48]
Mayrose, I.; Penn, O.; Erez, E.; Rubinstein, N.D.; Shlomi, T.; Freund, N.T.; Bublil, E.M.; Ruppin, E.; Sharan, R.; Gershoni, J.M.; Martz, E.; Pupko, T. Pepitope: Epitope mapping from affinity-selected peptides. Bioinformatics, 2007, 23(23), 3244-3246.
[49]
Huang, J.; Ru, B.; Zhu, P.; Nie, F.; Yang, J.; Wang, X.; Dai, P.; Lin, H.; Guo, F.B.; Rao, N. MimoDB 2.0: A mimotope database and beyond. Nucleic Acids Res., 2012, 40, D271-D277.
[50]
Skwarczynski, M.; Toth, I.; Andersen, P.; Doherty, T.M.; Wallach, J.C.; Ferrero, M.C.; Delpino, M.V.; Fossati, C.A.; Baldi, P.C.; Steer, A.C. Peptide-based synthetic vaccines. Chem. Sci., 2016, 7(2), 842-854.
[51]
Robinson, J.; Halliwell, J.A.; McWilliam, H.; Lopez, R.; Parham, P.; Marsh, S.G.E. The IMGT/HLA database. Nucleic Acids Res., 2013, 41(Database issue), D1222-D1227.
[52]
Robinson, J.; Halliwell, J.A.; Marsh, S.G.E. IMGT/HLA and the immuno polymorphism database. Methods Mol. Biol., 2014, 1184, 109-121.
[53]
Andersen, H.P.; Nielsen, M.; Lund, O. Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci., 2006, 15(11), 2558-2567.
[54]
Kulkarni-Kale, U.; Bhosle, S.; Kolaskar, A.S. CEP: A conformational epitope prediction server. Nucleic Acids Res, 2005, 33(Web Server issue), W168-W171.
[55]
Nielsen, M.; Lundegaard, C.; Lund, O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics, 2007, 8, 238.
[56]
Liang, S.; Liu, S.; Zhang, C.; Zhou, Y. A Simple reference state makes a significant improvement in near-native selections from structurally refined docking decoys. Proteins Struct. Funct. Genet., 2007, 69(2), 244-253.
[57]
Sweredoski, M.J.; Baldi, P. PEPITO: Improved discontinuous B-cell epitope prediction using multiple distance thresholds and half sphere exposure. Bioinformatics, 2008, 24(12), 1459-1460.
[58]
Qi, T.; Qiu, T.; Zhang, Q.; Tang, K.; Fan, Y.; Qiu, J.; Wu, D.; Zhang, W.; Chen, Y.; Gao, J.; Zhu, R.; Cao, Z. SEPPA 2.0 - more
refined server to predict spatial epitope considering species of
immune host and subcellular localization of protein antigen. Nucleic Acids Res, 2014, 42(Web Server issue), W59-W63.
[59]
Liang, S.; Zheng, D.; Standley, D.M.; Yao, B.; Zacharias, M.; Zhang, C. EPSVR and EPMeta: Prediction of antigenic epitopes using support vector regression and multiple server results. BMC Bioinformatics, 2010, 11, 381.
[60]
Ponomarenko, J.; Bui, H.H.; Li, W.; Fusseder, N.; Bourne, P.E.; Sette, A.; Peters, B. ElliPro: A new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics, 2008, 9(1), 514.
[61]
Rubinstein, N.D.; Mayrose, I.; Martz, E.; Pupko, T. Epitopia: A web-server for predicting B-cell epitopes. BMC Bioinformatics, 2009, 10, 287.
[62]
Ansari, H.R.; Raghava, G.P. Identification of conformational B-Cell epitopes in an antigen from its primary sequence. Immunome Res., 2010, 6(Suppl. 2), S2.
[63]
Schuler, M.M.; Nastke, M.D.; Stevanovikć, S. SYFPEITHI: Database for searching and T-cell epitope prediction. Methods Mol. Biol., 2007, 409, 75-93.
[64]
Azmi, F.; Fuaad, A.A.H.A.; Skwarczynski, M.; Toth, I. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum. Vaccin. Immunother., 2014, 10(3), 778-796.
[65]
Petrovsky, N.; Aguilar, J.C. Vaccine adjuvants: Current state and future trends. Immunol. Cell Biol., 2004, 82(5), 488-496.
[66]
Awate, S.; Babiuk, L.A.; Mutwiri, G. Mechanisms of action of adjuvants. Front. Immunol., 2013, 4, 114.
[67]
Excler, J.L.; Kim, J.H. Accelerating the development of a group A streptococcus vaccine: An urgent public health need. Clin. Exp. Vaccine Res., 2016, 5(2), 101-107.
[68]
Kao, D.J.; Churchill, M.E.A.; Irvin, R.T.; Hodges, R.S. Animal protection and structural studies of a consensus sequence vaccine targeting the receptor binding domain of the type IV pilus of pseudomonas aeruginosa. J. Mol. Biol., 2007, 374(2), 426-442.
[69]
Hussein, W.M.; Liu, T.Y.; Skwarczynski, M.; Toth, I. Toll-like receptor agonists: A patent review (2011 -2013). Expert Opin. Ther. Pat., 2014, 24(4), 453-470.
[70]
Marasini, N.; Skwarczynski, M.; Toth, I. Oral delivery of nanoparticle-based vaccines. Expert Rev. Vaccines, 2014, 13(11), 1361-1376.
[71]
Dürr, U.H.N.; Sudheendra, U.S.; Ramamoorthy, A. LL-37, the only
human member of the cathelicidin family of antimicrobial peptides. Biochim. Biophys. Acta - Biomembr, 2006, 1758(9), 1408-1425.
[72]
De Yang; Chen, Q.; Schmidt, A.P.; Anderson, G.M.; Wang, J.M.; Wooters, J.; Oppenheim, J.J.; Chertov, O. Ll-37, the neutrophil granule–and epithelial cell–derived cathelicidin, utilizes formyl peptide receptor-like 1 (Fprl1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med., 2000, 192(7), 1069-1074.
[73]
Zheng, Y.; Niyonsaba, F.; Ushio, H.; Nagaoka, I.; Ikeda, S.; Okumura, K.; Ogawa, H. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human α-defensins from neutrophils. Br. J. Dermatol., 2007, 157(6), 1124-1131.
[74]
Mookherjee, N.; Brown, K.L.; Bowdish, D.M.E.; Doria, S.; Falsafi, R.; Hokamp, K.; Roche, F.M.; Mu, R.; Doho, G.H.; Pistolic, J.; Powers, J.P.; Bryan, J.; Brinkman, F.S.; Hancock, R.E. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol., 2006, 176(4), 2455-2464.
[75]
Nijnik, A.; Pistolic, J.; Wyatt, A.; Tam, S.; Hancock, R.E.W. Human cathelicidin peptide LL-37 modulates the effects of IFN- on APCs. J. Immunol., 2009, 183(9), 5788-5798.
[76]
Steinstraesser, L.; Hirsch, T.; Schulte, M.; Kueckelhaus, M.; Jacobsen, F.; Mersch, E.A.; Stricker, I.; Afacan, N.; Jenssen, H.; Hancock, R.E.W.; Kindrachuk, J. Innate defense regulator peptide 1018 in wound healing and wound infection. PLoS One, 2012, 7(8), e39373.
[77]
Cirioni, O.; Giacometti, A.; Ghiselli, R.; Bergnach, C.; Orlando, F.; Silvestri, C.; Mocchegiani, F.; Licci, A.; Skerlavaj, B.; Rocchi, M.; Saba, V.; Zanetti, M.; Scalise, G. LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob. Agents Chemother., 2006, 50(5), 1672-1679.
[78]
Faber, C.; Stallmann, H.P.; Lyaruu, D.M.; Joosten, U.; Von Eiff, C.; Van Nieuw, A.A.; Wuisman, P.I.J.M. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob. Agents Chemother., 2005, 49(6), 2438-2444.
[79]
Papareddy, P.; Kalle, M.; Sørensen, O.E.; Malmsten, M.; Mörgelin, M.; Schmidtchen, A. The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. PLoS Pathog., 2013, 9(12), e1003803.
[80]
Huang, H.N.; Rajanbabu, V.; Pan, C.Y.; Chan, Y.L.; Hui, C.F.; Chen, J.Y.; Wu, C.J. Modulation of the immune-related gene responses to protect mice against Japanese encephalitis virus using the antimicrobial peptide, tilapia hepcidin 1-5. Biomaterials, 2011, 32(28), 6804-6814.
[81]
Huang, H.N.; Rajanbabu, V.; Pan, C.Y.; Chan, Y.L.; Wu, C.J.; Chen, J.Y. A cancer vaccine based on the marine antimicrobial peptide pardaxin (GE33) for control of bladder-associated tumors. Biomaterials, 2013, 34(38), 10151-10159.
[82]
Baindara, P.; Korpole, S.; Grover, V. Bacteriocins: Perspective for the development of novel anticancer drugs. Appl. Microbiol. Biotechnol., 2018, 102(24), 10393-10408.
[83]
Lewis, K. New approaches to antimicrobial discovery. Biochem. Pharmacol., 2017, 134, 87-98.
[84]
Cotter, P.D.; Ross, R.P.; Hill, C. Bacteriocins-a viable alternative to antibiotics? Nat. Rev. Microbiol., 2013, 11(2), 95-105.
[85]
Hancock, R.E.W.; Nijnik, A.; Philpott, D.J. Modulating immunity as a therapy for bacterial infections. Nat. Rev. Microbiol., 2012, 10(4), 243-254.
[86]
Ageitos, J.M.; Sánchez-Pérez, A.; Calo-Mata, P.; Villa, T.G. Antimicrobial Peptides (AMPs): Ancient compounds that represent novel weapons in the fight against bacteria. Biochem. Pharmacol., 2017, 133, 117-138.
[87]
Bechinger, B.; Gorr, S.U. Antimicrobial peptides: Mechanisms of action and resistance. J. Dent. Res., 2017, 96(3), 254-260.
[88]
Andersson, D.I.; Hughes, D.; Kubicek-Sutherland, J.Z. Mechanisms and consequences of bacterial resistance to antimicrobial peptides. Drug Resist. Updat., 2016, 26, 43-57.
[89]
Park, A.J.; Okhovat, J.P.; Kim, J. Antimicrobial peptides. In: Clinical And Basic Immunodermatology; 2nd Ed.; Gaspari, A.A.;
Tyring, S.K.; Kaplan, D.; Eds; Springer: Berlin, 2017; p. 81-95.